Vanda Pharmaceuticals posted a third-quarter loss of $0.37 per share. That was well ahead of the -$0.72 consensus, a 48.6% earnings surprise. Revenue rose 24.1% year over year to $69.82 million, beating the $65.87 million consensus by 6.0%. On the surface, revenue growth accelerated sharply. Sales were up 38% from Q2's $50.5 million and well above the 8% pace for the first nine months. But the beat came alongside a guidance reset. Full-year revenue guidance moved from $240-290 million to "greater than $240 million," which is effectively the old floor. The NEREUS outlook was also cut hard. That is the central tension: a strong quarter on paper, paired with a lower trajectory for the year and a launch slate running behind schedule.
The quality of the beat deserves scrutiny. Q3 revenue included about $7.0 million of HETLIOZ orders that shipped on June 29 but were recognized in July. The call also cited specialty pharmacy restocking. HETLIOZ sales jumped to $21.7 million from $5.6 million in Q2, yet nine-month HETLIOZ sales are still down 21% year over year, so the generic-erosion story has not reversed. Excluding the timing shift, revenue would have been roughly $63 million, short of consensus. The earnings line has its own nuance. Earnings grew only 2.6% year over year, and GAAP net loss was essentially flat at $22.6 million. Pre-tax loss actually improved, from $28.4 million to $22.4 million, but a $5.8 million tax benefit in the year-ago quarter flattered the comparison. The clearest genuine improvement was cost control. Operating expenses fell 18% sequentially to $93.3 million from $114.3 million, and the net loss narrowed from $62.5 million in Q2. Management guided to further declines as Phase III and launch-preparation work winds down.
Fanapt remains the engine, but it is slowing at the margin. Sales rose 24% year over year to $38.8 million. Weekly prescriptions hit an 11-year high of roughly 2,800 in September. However, new-to-brand prescription growth decelerated from +76% in Q1 to +32% in Q2 to +18% in Q3. Total prescription growth eased from 32% to 31% to 25%. The Fanapt-plus-BYSANTI sub-guide of $150-170 million was not reiterated. NEREUS is the bigger disappointment. Prescriptions and unique prescribers more than doubled after sales-force promotion began, but Q3 sales were only $1.6 million. Full-year NEREUS revenue is now expected below $10 million, versus $10-30 million previously, as consumer uptake proves slower.
The pipeline produced real news, though with caveats. NEREUS delivered a positive Phase III result in GLP-1-induced vomiting, and HETLIOZ succeeded in a pivotal study for Delayed Sleep-Wake Phase Disorder. Both are headed toward supplemental filings. Yet the NEREUS GLP-1 primary effect was a 27% relative reduction, versus 50% in Phase II, which tempers the commercial case. December is crowded with binary events: the Quimilza PDUFA date on December 12 and the HETLIOZ jet-lag hearing on December 14-18. The BYSANTI launch has slipped to Q4, with management hoping to launch before year-end. Its expected mid-30s gross-to-net, versus about 50% for Fanapt, matters because Fanapt faces loss of exclusivity around the end of 2027. The MDD readout has drifted again, to the first half of 2027, and the long-acting injectable program is being rethought.
Bears have legitimate ammunition on the balance sheet. Cash fell $29.5 million in the quarter to $140.5 million and is down $123.4 million since December. The prior "funded through end-2027" language was not repeated. Falling opex helps, but the runway now depends heavily on BYSANTI execution and the December outcomes.
The market had largely braced for disappointment. Shares closed at $3.99 the day before the report. That is down 14.0% since the open after the August release and 36.4% below the 200-day moving average of $6.27. The stock sat just 3% above the 52-week low of $3.88 set on October 23, far from the inter-earnings high of $5.64 in early September. Investor sentiment moved modestly more negative, from -0.0143 to -0.0912. The Earnings Whispers price and AVWAP trend readings remain negative.
The bottom line is that Vanda delivered a headline beat and meaningful cost discipline, but much of the revenue upside was timing-driven. Meanwhile, guidance, NEREUS expectations, Fanapt's new-patient growth, and the BYSANTI timeline all moved the wrong way. With shares near their lows and cash declining, the investment case now rests on December's regulatory events and a timely BYSANTI launch rather than on the quarter itself.